Member Info for Moneymunch

Lol....priceless...ha ha ha ho....:-))))

6. Conclusions

In summary, there is mounting supporting evidence that SFN may have therapeutic potential in kidney disease by stimulating the NRF2 pathway (Figure 2). SFN is currently in clinical trials for cancer of the breast, lung, and prostate, as well as autism and schizophrenia (Clinicaltrials.gov). However, currently no clinical study has been performed to assess the effect of SFN in CKD. As SFN and its metabolites are cleared by the kidney [144], safety and efficacy should first be established in patients with kidney disease, particularly in those with more advanced stages of CKD. Once established, large, randomized, placebo-controlled trials are needed to determine the effect of SFN on long-term outcomes such as disease progression and mortality in patients with CKD, and whether the effect is modified by genetics in a precision medicine approach.

https://www.mdpi.com/2072-6643/13/1/266/htm

Very interesting!!!!, Latest research from Prof Thu Le and University of Rochester, New York where Evgen have been in collaboration since February 2020. Gla ;-)

February 2020

Professor Le and colleagues have previously published research showing an association between CKD patients with the GSTM1 null allele and more rapid CKD progression, and also that consumption of cruciferous vegetables (a source of sulforaphane) is associated with lower risks of kidney failure, with stronger effects in those having the GSTM1 null allele. On this basis, Professor Le approached Evgen, the developer of SFX-01, a stable form of sulforaphane that has demonstrated excellent safety and tolerability in previous clinical trials.

Thu Le, Professor of Medicine, and Chief of the Division of Nephrology at the University of Rochester Medical Center said: "We are pleased that Evgen will support our plans to undertake a clinical trial on SFX-01 in patients with CKD. Increased oxidative stress is a major molecular underpinning of CKD progression and our research suggests that patients with the GSTM1 null allele may particularly benefit from sulforaphane treatment via SFX-01 dosing."

https://uk.advfn.com/stock-market/london/evgen-pharma-EVG/share-news/Evgen-Pharma-PLC-University-of-Rochester-Collabora/81743058

....................

January 2021

Eat Your Broccoli: Oxidative Stress, NRF2, and Sulforaphane in Chronic Kidney Disease

January 2021 Nutrients 13(1):266

DOI: 10.3390/nu13010266
Authors:
Scott Liebman

University of Rochester

Thu H Le

University of Rochester Medical Center

Abstract and Figures

The mainstay of therapy for chronic kidney disease is control of blood pressure and proteinuria through the use of angiotensin-converting enzyme inhibitors (ACE-Is) or angiotensin receptor blockers (ARBs) that were introduced more than 20 years ago. Yet, many chronic kidney disease (CKD) patients still progress to end-stage kidney disease—the ultimate in failed prevention. While increased oxidative stress is a major molecular underpinning of CKD progression, no treatment modality specifically targeting oxidative stress has been established clinically. Here, we review the influence of oxidative stress in CKD, and discuss regarding the role of the Nrf2 pathway in kidney disease from studies using genetic and pharmacologic approaches in animal models and clinical trials. We will then focus on the promising therapeutic potential of sulforaphane, an isothiocyanate derived from cruciferous vegetables that has garnered significant attention over the past decade for its potent Nrf2-activating effect, and implications for precision medicine.

https://www.researchgate.net/publication/348623288_Eat_Your_Broccoli_Oxidative_Stress_NRF2_and_Sulforaphane_in_Chronic_Kidney_Disease

Very interesting!!!!, Latest research from Prof Thu Le and University of Rochester, New York where Evgen have been in collaboration since February 2020. Gla ;-)

February 2020

Professor Le and colleagues have previously published research showing an association between CKD patients with the GSTM1 null allele and more rapid CKD progression, and also that consumption of cruciferous vegetables (a source of sulforaphane) is associated with lower risks of kidney failure, with stronger effects in those having the GSTM1 null allele. On this basis, Professor Le approached Evgen, the developer of SFX-01, a stable form of sulforaphane that has demonstrated excellent safety and tolerability in previous clinical trials.

Thu Le, Professor of Medicine, and Chief of the Division of Nephrology at the University of Rochester Medical Center said: "We are pleased that Evgen will support our plans to undertake a clinical trial on SFX-01 in patients with CKD. Increased oxidative stress is a major molecular underpinning of CKD progression and our research suggests that patients with the GSTM1 null allele may particularly benefit from sulforaphane treatment via SFX-01 dosing."

https://uk.advfn.com/stock-market/london/evgen-pharma-EVG/share-news/Evgen-Pharma-PLC-University-of-Rochester-Collabora/81743058

....................

January 2021

Eat Your Broccoli: Oxidative Stress, NRF2, and Sulforaphane in Chronic Kidney Disease

January 2021 Nutrients 13(1):266

DOI: 10.3390/nu13010266
Authors:
Scott Liebman

University of Rochester

Thu H Le

University of Rochester Medical Center

Abstract and Figures

The mainstay of therapy for chronic kidney disease is control of blood pressure and proteinuria through the use of angiotensin-converting enzyme inhibitors (ACE-Is) or angiotensin receptor blockers (ARBs) that were introduced more than 20 years ago. Yet, many chronic kidney disease (CKD) patients still progress to end-stage kidney disease—the ultimate in failed prevention. While increased oxidative stress is a major molecular underpinning of CKD progression, no treatment modality specifically targeting oxidative stress has been established clinically. Here, we review the influence of oxidative stress in CKD, and discuss regarding the role of the Nrf2 pathway in kidney disease from studies using genetic and pharmacologic approaches in animal models and clinical trials. We will then focus on the promising therapeutic potential of sulforaphane, an isothiocyanate derived from cruciferous vegetables that has garnered significant attention over the past decade for its potent Nrf2-activating effect, and implications for precision medicine.

https://www.researchgate.net/publication/348623288_Eat_Your_Broccoli_Oxidative_Stress_NRF2_and_Sulforaphane_in_Chronic_Kidney_Disease

My request went in on deadline day for allocation and additional shares and my account was debited the next, they're both showing on my portfolio list , number of shares, but all financial details are still at zero, including cost , until Thursday I assume?

Rob Clarke
@RobClarkeLab
·
1h

It’s been a great year for @MCRBreastCentre activities with your invaluable input as MBC Research Coordinator. Looking forward to to another successful year and hopefully some face to face meetings and seminars.

@BreastCancerNow
@TheChristie
@MCRCnews

https://twitter.com/robclarkelab?lang=en

Thanks for that Compoundinterest, obviously i do convey my positive opinion , but it's backed up by solid and relevant research, something that those with a negative slant on Evgen's prospects and potential have difficutly with.....anyways, each to their own, looking forward to 4th March Admission day when Evgen will be fully funded to "dramatically accelerate" development of theirmultiple disease target pipeline......i'm sure Huw will have plenty of postive material updates in the coming weeks, to drive the sp to new highs.....Fill Ya Boots.....back to Double figures in a blink. ;-)

ps Starjump, and what's your username over at Advfn , as a matter of interest????

You should try reading some than mate, you might learn a thing or two, unless you have a jaundiced disposition of course with a slant towards the negative. Gl ;-)

"While the recent returns on many investments in listed biotechs is impressive, some investors are recognising that even they can be dwarfed if they give their backing to the right company early enough in its development. Those investors know that the best value will come from investing early in a company at cheaper valuations, with the rewards coming if that company has a product approved. The risk/reward analysis has been tipped in favour of reward by the evident strength of biotechs over the last 12 months."

" Two of the most recent examples are the placings by Evgen Pharma plc, the clinical stage company focussed on the treatment of cancer and inflammation, and Synairgen plc, the respiratory drug discovery and development company, both listed on AIM. These biotechs are suddenly in the enviable position of having to choose between scaling back allocations or only accepting the money on the table from specific investors."

.........................

Booming biotech sector allows for choices over investment

Out-Law Analysis | 23 Feb 2021

https://www.pinsentmasons.com/out-law/analysis/booming-biotech-sector-allows-for-choices-over-investment

STAR-COVID19 study is sponsored by the University of Dundee and funded byLifeArc

The study is recruiting patients with ARDS of any origin, is not limited to COVID-19 positive patients.

ARDS is a long-standing serious health problem and will remain so long after the current pandemic subsides.

Pre-COVID there were 190,000 patients and 30,000 ICU beds p.a. utilised in the USA alone

Glioblastoma

Very poor life expectancy, average time to death after diagnosis 14 months, 5% five-year survival.

Current treatments include surgical resection, radiotherapy and chemotherapy, frequent relapses.

In vitro studies with patient-derived cell lines showed dose-dependent reduction in proliferation and migration.

In orthotopic xenograft models, treatment with SFX-01 increased disease-free survival and lengthened tumour progression times, an effect that is synergistic with radiotherapy.

Use of Proceeds

The Fundraising will raise gross proceeds of up to GBP11 million - admission date 4th March 2021

The net proceeds of the Fundraising are intended to be used as follows:

to fund further preclinical work for metastatic breast cancer (mBC), glioma and a further cancer indication yet to be announced;

subject to further pre-clinical progress, potentially fund a clinical trial in glioma patients;

to complete the formulation and scale up manufacturing of SFX-01;

to complete all preparatory work required to file an Investigational New Drug application in the US in respect of SFX-01; and

to fund the Group's operations through to mid-2023 including two key senior hires, being a Chief Business Officer and a Chief Scientific and Medical Officer.

Summary

Capital efficient, virtual, focus: cancer and inflammation/ARDS-COVID

Granted IP on SFX-01 and analogues

Multiple value inflection points, licensing deals in our therapy areas range from $90m to $325m with $11m to $35m upfront and double digit royalties

Highly experienced board and management

Non-pharma partnership – market launch 2023

Lol SuperSB, on the contrary, a fully funded Evgen with multiple shots on multiple targets looks rather exciting imho...Gl ;-)

Developing a new class of pharmaceuticals- based on highly biologically active “sulforaphane”- applications in multiple therapeutic areas based on a network of targets

Four target diseases in cancer and inflammation, each with high unmet clinical needs

Unique platform technology– Sulforadex, stabilises unstable sulforaphane, lead SFX-01

Strong, granted IP covering composition, manufacturing and novel derivatives

Highly experienced board and management

Businessmodel: establish proof of concept and partner. Multiple value inflection points

Recent Achievements

mBC Commencementof pre-clinical collaboration with University of Manchester and The Christie Hospital. Generate data to optimise positioning of SFX-01 in breast cancer treatment following promising Phase2a clinical data.

Out license marketaverage: $19m up front, $144m total, 10-14% royalty

ARDS/COVID First patient recruited in STAR ARDS trial. Now 102 patients recruited
190,000 ARDS patients in USA/year pre COVID

Out license market average: $35m up front, total $325m, royalty n/a

GLIOMA Receipt of powerful pre-clinical data including significant survival benefit.

Out licence market average $11m up front, $90m total, 8-12% royalty

ONC3 Collaboration underway with a prestigious academic institution on a target relevant to solid tumours and bloodcancers

PARTNER Sulforadex technology licence concluded with Juvenescence for non-pharmaceutical applications using naturally derived sulforaphane $10.5m in milestones/options plus royalty. Market launch in 2023

SFX-01 Can Be Life-changing

Diagnosed age 40 ER+ Her2- early Breast Cancer

Received surgery, chemotherapy and tamoxifen

After 5 years diagnosed with pleural nodules

Enrolled into Phase 2a trial May 2017 –tamoxifen + SFX-01

Objective response to treatment, very well tolerated, able to continue her life caring for her 2 young children and husband with head and neck cancer

Entered the extended use programme and had Stable Disease for a total of 597 days, including tumour shrinkage of 63% from baseline

5 patients remained progression free after 1 year of treatment with SFX-01 + ET

Star-Covid19 Study

Strong evidence that Nrf2 activation is relevant in acute respiratory distress syndrome(ARDS).

The Nrf2 pathway has been foundto be suppressed in lung biopsies from COVID19patients

Sulforaphane is one of very few activators of the transcription factor Nrf2- via suppression of KEAP1, allowing Nrf2 to restore redox homeostasis, protect against oxidative stress and provide suppression of inflammatory mediators

SFX-01 is the only synthetic druggable form of sulforaphane suitable for clinical trials and was selected for the COVID study

This Phase II/III trial is a randomised, placebo-controlled trial, sponsored by the University of Dundee and funded by the UK charity LifeArc. It is investigating whether the Company's lead asset, SFX-01, can reduce the severity, or prevent the onset of, acute respiratory distress syndrome ("ARDS") in patients with suspected COVID-19. Patients may be included in the study if they are infected with SARS-CoV-2 or another respiratory infections causing community-acquired pneumonia.

The trial design includes an assessment of safety and futility by a Data Safety and Monitoring Board ("DSMB") who will review unblinded data on the first 100 patients treated. In addition to the DSMB safety and futility assessment, Dundee University ("the Sponsor") has decided to review the top-level unblinded data in a preliminary assessment of possible efficacy. This may lead to adjustments to the design of the trial for remaining patients, including in patient numbers, and possibly early termination for either safety, futility or alternatively, strong efficacy. It is expected that this initial data will be available during the second quarter of calendar 2021.

Covid-19: How the pandemic forged One Dundee

Published on 17 February 2021

The University has always promoted a message of “One Dundee” - of a community united in good times and bad. That ethos has been exemplified by the response of the University and our community to the Covid-19 pandemic over the past year.

Having forged a reputation as one of the country’s leading lung experts, Professor Chalmers has become a regular fixture on television and radio, updating the public on his work.

“Right from the beginning of the pandemic, our scientists were here, collecting samples from people with Covid-19, helping to treat them, and trying to find new treatments by conducting vital clinical trials.

“One of the major challenges traditionally faced by scientists is the time taken to write grants for research funding. We didn’t have that time during the pandemic, but we worked with great partners, like the British Lung Foundation, that allowed us to redeploy staff that allowed us to work on Covid-19 projects.

“While an exciting time for scientists, we have always been aware of the threat posed by this illness and the sacrifices being made by so many people as we adjusted to living with it. What we can say, however, is that the research undertaken here has really helped to improve outcomes for people suffering from this disease.

“We started two major randomised trials of therapies, including the first major clinical trial led from Scotland. We also started a unique collaboration between scientists and frontline clinicians working with Covid-19 patients. Working together has helped us to produce results in a rapid timeframe.”

https://www.dundee.ac.uk/stories/covid-19-how-pandemic-forged-one-dundee

This is will fly in the coming week or so I reckon, fully funded for the foreseeable, multiple shots on multiple Transformational targets, and I also reckon Huw will have one or two updates to release very soon after the 4th March, admission date, to get the so heading North. Gla holders :-)

9p trades are buys...Gla ;-)

Yep, let's wait and see.....those who are thinking they can get back in at 8p are mistaken imho, unless they've taken up their 8p entitlement of course, which is exactly what iv'e done......a sudden and significant re-rate very likely next week, where else can you find multiple shots on multiple targets with raft of potential near term that's expected very soon from from such a well funded Bio at 8p a share...?????? Gla Holders......true and fair value to reflect Evgen's amazing prospects will prevail. ;-)

ps i'm expecting a big bounce tomorrow with the 8p entitlement deadline ending today....On and UP!!! ;-)

This one's different bigdanny imho..........we're going to have double the shares next week , and that will give Evgen a market cap of c£20m at 8p a share, but they're going to have c£13m cash in the bank, enough funding for the next 2 years according to the CEO, which will "dramatically accelerate development" of their multiple disease target pipeline , anyone of the disease targets could provide transformational upside on success, and we're also awaiting near and mid term newsflow from across their pipeline where positive data could drive the sp to news highs .

We're also awaiting potential game changing news on their Covid/ARDS trial from the assessment of safety and futility by a Data Safety and Monitoring Board ("DSMB") who will review unblinded data on the first 100 patients treated. In addition to the DSMB safety and futility assessment, Dundee University ("the Sponsor") has decided to review the top-level unblinded data in a preliminary assessment of possible efficacy. This may lead to adjustments to the design of the trial for remaining patients, including in patient numbers, and possibly early termination for either safety, futility or alternatively, strong efficacy. It is expected that this initial data will be available during the second quarter of calendar 2021. Positive data will be transformational for all concerned.

I personally can't think of many other Bio's with a similar modest market cap and so well funded, with so many shots on multiple targets from a pipeline so advanced. The current sp sits at a 14% premium to the 8p placing shares. The £10m oversubscribed placing has been taken up by existing Major shareholders and new high quality investors, all of whom must be very confident of Evgen's near, mid and long term prospects going forward, and so i'd be very surprised if the sp heads towards the 8p placing price next week, given Evgen's undoubted transformational prospects and potential and exceptionally strong cash position.....and so i reckon new investors will start flooding in from next week to drive the sp upwards and postive news could drop at anytime to drive it up further...watch this space!!! Gl ;-)

Last day for 8p entitlement, a big week ahead and plenty of potential positive newsflow thereafter to drive the sp to new highs, with Evgen fully funded for the next couple of years...Exciting times. Gla holders:-)